In recent years, two non-invasive biomarkers that can reliably detect and prognosticate CRC have been discovered in clinical settings: the Kirsten rat sarcoma viral oncogene homolog (KRAS) and the B-raf serine/threonine kinase proto-oncogene (BRAF) [68,69]. Here, KRAS is linked to colorectal carcinoma.